New Calera program aims to help law enforcement responses
CALERA, Ala. (WIAT) — A new program in Calera aims to help first responders provide better care for the community.
The C.A.R.E. Network stands for Calera Awareness and Response for Everyone. A Calera dispatcher designed it to help give better responses to those with mental illnesses and disabilities.
'I've worked at a few different law enforcement agencies, but that's one thing I've always felt was a need was a way that we could communicate and maintain our safety and our relationships with our entire community, including our special needs community,' said Jessica Davis, the brain behind the C.A.R.E. Network.
C.A.R.E. gives people in the community the ability to fill out a form for the police and fire departments letting them know of any mental illnesses or disabilities. This includes anything from Alzheimer's disease to autism spectrum disorder to Down syndrome to mobility, hearing, vision and speech impairments. By filling the application out, dispatchers can let police officers and firefighters know exactly what they'll be walking in to.
'It's went further so far than I originally anticipated it to,' Davis said. 'Within an hour and a half [on the first day], I believe, we had over 20 applicants for the program and then now, I've had a few different agencies, other law enforcement agencies, reach out to me about how we went about setting this program up and the things that we're doing now to get it out there and make sure our citizens know about it.'
Parties react to Sen. Tommy Tuberville's run for governor of Alabama
Calera Police Chief David Hyche was immediately on board with Davis' idea. For him, this program is personal.
'I have a special needs daughter, and I remember when she was younger, a big concern that my wife and I had was that if we had a tragic event happen at our house or in the vehicle, law enforcement or fire services might not know how to communicate with her,' Hyche said. 'She's blind and autistic, so a firefighter in their gear or a police officer, it would be unusual sounds and touch, and the feel and the sound of a firefighter in turnout gear would be like a monster to her.'
Hyche said it's voluntary to fill out the C.A.R.E. Network application, and information is kept private in the system.
'The more information we can have here at the police department, the better and the safer for everyone,' he said. 'It's really used just to make it safer for both the officers as well as the families.'
Hyche said he's already talked with some lawmakers and hopes to see this program go statewide.
'My daughter was a part of several different organizations, and I've been around a lot of autistic adults and children,' Hyche said. 'I could see how their misinterpretation of signals could be seen by law enforcement as aggressive or hostile, and the law enforcement officer might not know any different. These are absolutely signals that 'I am in danger,' when in reality it might just be the way that the autistic person responds to certain stimuli.'
If you would like to be a part of the C.A.R.E. Network, you can fill out an application here or in person at the Calera Police Department.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
New Study Finds That A Blood Test For Diabetes Might Actually Predict Alzheimer's Progression
A new study suggests a simple blood test could tell who is at higher risk for rapid cognitive decline with Alzheimer's. The study found that people with higher insulin resistance were up to four times more likely to have rapid cognitive decline. Here's what to know about the test and how to get one. Historically, it has been quite difficult for doctors to predict how fast patients will experience cognitive decline with Alzheimer's disease, especially since the neurodegenerative disease impacts people differently based on a slew of factors. But new research has discovered that a specific blood test may help doctors get more answers, which could, in theory, help them respond more quickly with appropriate treatment and providing patients with more information. (But of course, experts first need to gather more data and perform further studies on the test.) The test measures insulin resistance, a condition where the body's cells don't respond properly to insulin, a hormone that helps escort blood sugar into cells for energy. The latest study finds a link between insulin resistance and Alzheimer's disease progression, helping doctors and patients glean more information about what may be in store. Here's what the study found, plus what neurologists want you to know. Meet the experts: Clifford Segil, DO, is a neurologist at Providence Saint John's Health Center in Santa Monica, CA; Amit Sachdev, MD, MS, is the medical director in the Department of Neurology at Michigan State University. The study, which was presented at the European Academy of Neurology Congress 2025, analyzed health records of 315 people without diabetes who had cognitive deficits. Of those, 200 had confirmed cases of Alzheimer's disease. All of the patients had their insulin resistance checked using something called the Triglyceride-Glucose (TyG) index, a way to check insulin resistance, based on fasting triglyceride (a type of fat in the blood) and blood sugar levels, at the start of the study and three years later. The researchers discovered that patients in the mild cognitive impairment group with higher TyG levels had their cognitive health deteriorate a lot faster than those who were lower on the TyG index. Ultimately, the researchers found that people with higher TyG levels were up to four times more likely to have rapid cognitive decline compared to those who were lower on the scale. For starters, this type of blood test isn't actually new. We're just discovering new ways it can be used. The TyG index is already used to look for insulin resistance in people, so technically, you could get this test now if your doctor thought that it was medically appropriate. Just know that it's usually used in the context of diabetes or when your doctor suspects you might have diabetes. The test appears to be pretty accurate in predicting rapid mental decline. The researchers found that people with high TyG ended up losing more than 2.5 points on the Mini Mental State Examination per year, which is a standardized test used to look at cognitive function in older adults. In Alzheimer's disease, insulin resistance is thought to interfere with how the brain uses glucose (blood sugar). It's also believed to promote the build-up of amyloid, or proteins deposits in the brain that are linked with Alzheimer's disease. Additionally, insulin resistance can disrupt the blood-brain barrier and fuel inflammation in the brain. All of these are linked with neurodegenerative diseases like Alzheimer's disease. 'Insulin resistance often reflects features of overall health," says Amit Sachdev, MD, MS, medical director in the Department of Neurology at Michigan State University, pointing out that a major contributor to insulin resistance is higher bodyweight. 'If the overall health of the body is not optimal, then the brain will not be well supported and can be less resilient.' But the link between insulin resistance and Alzheimer's disease is still being explored, says Clifford Segil, DO, a neurologist at Providence Saint John's Health Center in Santa Monica, CA. So, while it's clear that it seems to play some role, it's hard to tell what it's specifically doing as it relates to brain health. Your doctor can order one of these tests for you. However, neurologists say there are better options right now if you're concerned about Alzheimer's disease development and are looking for answers. 'Some tests that are more specific for Alzheimer's are serum amyloid and tau levels,' Dr. Sachdev sys. 'Tests that help predict risk for the anti-amyloid therapies used in Alzheimer's is the APO-E genotype. These studies are useful today in understand risk of dementia, type of dementia, and risk of treatment.' Dr. Segil says that doctors are 'extremely cautious' about using blood tests like TyG to determine if someone is at risk for developing dementia in the first place. 'There remains an extremely high number of false positive results in patients receiving various blood tests being marketed to determine if you are at risk for getting dementia,' he says. However, this specific study is exploring the test to see how quickly someone who already has cognitive decline will progress—and that usage is still being explored. All of this doesn't mean you can't or shouldn't get a TyG test. Just know that your doctor is more likely to use it while checking you for early signs of diabetes versus Alzheimer's disease right now. You Might Also Like Jennifer Garner Swears By This Retinol Eye Cream These New Kicks Will Help You Smash Your Cross-Training Goals
Engadget
a day ago
- Engadget
Peter Thiel is utterly wrong about Alzheimer's
The New York Times ran a lengthy interview this morning between columnist Ross Douthat and venture capitalist and PayPal founder Peter Thiel. There's a reason it was published in the opinion section. Thiel, a Trump booster whose allies — including Vice President JD Vance — now litter the White House, was given free reign to discuss a variety of topics across over an hour of softball questions. Is Greta Thunberg the literal antichrist? Are the three predominant ideological schools in Europe environmentalism, "Islamic Shariah law" and "Chinese Communist totalitarian takeover"? Is AI "woke" and capable of following Elon Musk to Mars? Peter seems to think so! Perhaps the "just asking questions" school of journalism could add " hey, what the fuck are you talking about " to its repertoire. Admittedly, many of these assertions fall squarely into the realm of things that exist within Thiel's mind palace rather than verifiable facts, with at least one notable exception. Relatively early in their chat, Peter tells Ross the following [emphasis ours]: If we look at biotech, something like dementia, Alzheimer's — we've made zero progress in 40 to 50 years. People are completely stuck on beta amyloids. It's obviously not working. It's just some kind of a stupid racket where the people are just reinforcing themselves. It's a pretty bold claim! It's also completely untrue. "There was no treatment 40 or 50 years ago for Alzheimer's disease," Sterling Johnson, a professor of Geriatrics and Gerontology at the University of Wisconsin, Madison, told Engadget. "What we've been able to do in the last 20 years has been actually pretty extraordinary. We've developed markers that help us identify when this disease starts, using the using amyloid markers and tau biomarkers, we know that the disease actually begins 20 years before the symptoms do, and that is a critical thing to know if we are going to prevent this disease." At the moment, Alzheimer's remains incurable. But the absence of a miracle cure does not negate the accomplishments thus far in detection and prevention. "The first treatments were these window dressing treatments. It's like treating the symptoms like you would treat a cold [...] The first generation of amyloid therapy was that kind of approach where it just addressed the symptoms by amping up the neurons and increasing the neurotransmitters available to the to the brain cells." Johnson, whose team runs one of the largest and longest studies on people at risk for developing Alzheimer's diseases, added, "Now we have opportunities to actually modify the disease biology through the amyloid pathway, but also we're focused on the other proteinopathy — which is tau — and there's clinical trials underway." Thiel, a well-known advocate for advancements in radical life extension (including a reported interest in injecting himself with the blood of young people) sees the state of scientific research in this area as sluggish and risk averse. But the groundbreaking work is happening at this moment. Professor Johnson pointed to a monoclonal antibody called gantenerumab. In an early test of 73 participants with inherited mutations that would cause them to overproduce amyloid in the brain, it cut the number of participants who developed Alzheimer's symptoms practically in half. "The big phase three prevention trials [of gantenerumab] are happening right now," For someone who fashions himself as a heterodox thinker, Thiel certainly seems to have stumbled on a remarkably similar talking point to current Trump administration FDA head Robert F Kennedy Jr. "Alzheimer's is a very, very good example of how [National Institute of Health] has gone off the rails over the past 20 years ago with research on amyloid plaques" Kennedy said at a Department of Health budgetary hearing last month. He claimed the NIH was "cutting off any other hypothesis" due to "corruption." Unsurprisingly, the Alzheimer's Association has called this "demonstrably false." "In reality, over the most recent 10 years available (2014-2023), less than 14% of new National Institutes of Health (NIH) Alzheimer's projects focused on amyloid beta as the therapeutic target," the organization wrote, "As of September 2024, the National Institute on Aging was investing in 495 pharmacological and non-pharmacological trials. To state that Alzheimer's research is focused on amyloid to the exclusion of other targets is clearly wrong." If I, personally, wanted more robust medical research and a chance an eternal life (I don't), greasing the wheels of an administration broadly gutting funding for science would be a strange way to make that happen. But this is the sort of incoherence we've come to expect from tech oligarchs: they say what benefits them, even if it's nonsense on its face, even if a moment's reflection reveals it to be patently false. What's embarrassing is the paper of record giving them free reign to do it.
Yahoo
a day ago
- Yahoo
Scientists Found a Secret Weapon That May Stop Blindness Before It Starts
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." Here's what you'll learn when you read this story: Age-related macular degeneration (AMD) is the most common cause of blindness in people over the age of 50, and while there are treatments, there are few options to stop the degradation in its tracks once the disease has taken hold. A new study finds that the molecule apolipoprotein M, or ApoM—known for its protective and anti-inflammatory qualities—could help clear away vision-damaging cholesterol deposits as they accumulate in the retina. Not only could an increased dose of ApoM in the bloodstream help ward off AMD, the molecule could be useful in treating certain heart ailments as well. The human eye is a wonder of evolution, but it's also host to a variety of maladies that can make a once clear, crisp, and colorful world a dull and blurry one. One of the most prevalent of these vision-based ailments is age-related macular degeneration (AMD)—when the central part of our retina (the macula) begins to waste away. This begins with changes in the retinal pigmented epithelium, which guard the inside and outside of the retinal, as they begin failing to clear waste away from the eye. AMD is the leading cause of blindness in people over 50, and the disease leads to an overall loss of central vision, which is needed for reading, driving, and recognizing faces (all pretty important stuff). Now, a team of researchers—led by scientists at Washington University (WashU) in St. Louis—has found a handy molecule that could possibly help treat AMD as well as certain ailments in the heart. Known as apolipoprotein M, or ApoM, this molecule is a lipocalin (an extracellular protein capable of transporting hydrophobic molecules) that binds with the bioactive lipid sphingosine-1-phosphate, or S1p. The new study found that when this protein was increased in the bloodstream, it helped clear away the cholesterol-rich deposits in the eye that lead to AMD. The results of the study were published in the journal Nature Communications. 'Current therapies that reduce the chance of further vision loss are limited to only the most advanced stages of macular degeneration and do not reverse the disease,' Rajendra S. Apte, the senior author of the study from WashU, said in a press statement. 'Our findings suggest that developing treatments that increase ApoM levels could treat or even prevent the disease and therefore preserve people's vision as they age.' These cholesterol deposits are only the beginning of a patient's problems when experiencing AMD. Someone might not experience any vision loss in the early stages of this disease, but the deposits eventually increase inflammation and eventually lead to 'dry' macular degeneration caused by geographic atrophy—a kind of neurodegeneration that's also found in Alzheimer's patients. While treatable, this advanced stage of AMD is not reversible. However, new treatment using ApoM—which, in recent years, has been shown to be a protective molecule with anti-inflammatory attributes—could potentially stop AMD before it develops past the point of no return. When tested in mice, the rodents showed evidence of improved retinal health, including both better performance from light-sensing cells in the retina and reduced cholesterol build-up. Of course, there's another area of the body particularly sensitive to cholesterol—the heart. Amazingly, the researchers also found that ApoM could also play a pivotal role in treating certain heart diseases. 'One of the exciting things about this collaboration is realizing the links between retinal pigment epithelial cells and heart muscle cells, which are both vulnerable to low ApoM,' Ali Javeheri, a co-author of the study from WashU, said in a press statement. 'It is possible that the interaction between ApoM and S1P is regulating cholesterol metabolism in both cell types.' The eye is undoubtedly one of the most impressive organs we have, and a new era of vision medicine aims to keep it that way, even as we age through the years. You Might Also Like The Do's and Don'ts of Using Painter's Tape The Best Portable BBQ Grills for Cooking Anywhere Can a Smart Watch Prolong Your Life?
